Bri2 BRICHOS client specificity and chaperone activity are governed by assembly state.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 29234026.
- Also identified by DOI 10.1038/s41467-017-02056-4 and PMC identifier 5727130.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Protein misfolding and aggregation is increasingly being recognized as a cause of disease. In Alzheimer's disease the amyloid-β peptide (Aβ) misfolds into neurotoxic oligomers and assembles into amyloid fibrils. The Bri2 protein associated with Familial British and Danish dementias contains a BRICHOS domain, which reduces Aβ fibrillization as well as neurotoxicity in vitro and in a Drosophila model, but also rescues proteins from irreversible non-fibrillar aggregation. How these different activities are mediated is not known. Here we show that Bri2 BRICHOS monomers potently prevent neuronal network toxicity of Aβ, while dimers strongly suppress Aβ fibril formation. The dimers assemble into high-molecular-weight oligomers with an apparent two-fold symmetry, which are efficient inhibitors of non-fibrillar protein aggregation. These results indicate that Bri2 BRICHOS affects qualitatively different aspects of protein misfolding and toxicity via different quaternary structures, suggesting a means to generate molecular chaperone diversity.
Medical subject headings
- Amyloid beta-Peptides
- Cataract
- Cerebellar Ataxia
- Cerebral Amyloid Angiopathy, Familial
- Deafness
- Dementia
- Membrane Glycoproteins
- Protein Aggregation, Pathological